albuterol (Ventolin)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (5)
US
  • Bronchospasm Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease.
  • Exercise-Induced Bronchospasm Albuterol Sulfate HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.
Product first approved 2001Outside this platform's coverageFDA label
IE
  • Ventolin Diskus 200 mcg inhalation powder (PA1077/049/011): asthma, chronic bronchitis, emphysema; marketed; holder GlaxoSmithKline (Ireland) Limitedhpra.ie
  • Same GSK Ventolin product as the 'albuterol (Ventolin)' row (Ventolin Diskus 200 mcg, PA1077/049/011); the two rows look like duplicates of one assethpra.ie
  • Ventolin Nebules 2.5 mg nebuliser solution (PA1077/049/005); register shows not marketed; indication not checkedOutside this platform's coveragehpra.ie
Product first approved 1984

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (43)
Asthma
NCT06154304 · Cipla Ltd.
2023-12-06 – 2024-11-29 · Bronchial Asthma
What this study did
NCT05884970 · Canisius-Wilhelmina Hospital
2023-03-30 – 2024-09 · Agents, Anti Asthmatic, Asthma in Children
What this study did
NCT02969408 · Teva Branded Pharmaceutical Products R&D, Inc.
2017-02-13 – 2018-02-02 · Asthma
What this study did
NCT02502734 · GlaxoSmithKline
2015-09-07 – 2015-12-21 · Asthma
What this study did
NCT02175771 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-07 – 2015-07 · Persistent Asthma
What this study did
NCT02126839 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-05 – 2015-02 · Asthma
What this study did
NCT01698320 · Teva Branded Pharmaceutical Products R&D, Inc.
2012-10 – 2013-12 · Asthma
What this study did
NCT01424813 · Teva Branded Pharmaceutical Products R&D, Inc.
2012-12 – 2013-11 · Asthma
What this study did
NCT01747629 · Teva Branded Pharmaceutical Products R&D, Inc.
2012-12 – 2013-11 · Asthma
What this study did
NCT01857323 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-05 – 2013-09 · Asthma, Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01687296 · GlaxoSmithKline
2012-11-12 – 2013-06-21 · Asthma
What this study did
NCT01431950 · GlaxoSmithKline
2011-09 – 2012-10 · Asthma
What this study did
NCT01218009 · Teva Branded Pharmaceutical Products R&D, Inc.
2010-10 – 2010-12 · Asthma
What this study did
NCT01076322 · Taiwan Otsuka Pharm. Co., Ltd
2009-03 – 2010-06 · Asthma
What this study did
NCT00990847 · PT Otsuka Indonesia
2007-06 – 2008-08 · Moderate Acute Asthma
What this study did
NCT00384189 · AstraZeneca
2006-09 – 2008-08 · Asthma
What this study did
NCT00577655 · Teva Branded Pharmaceutical Products R&D, Inc.
2007-08 – 2008-07 · Asthma
What this study did
NCT00085774 · Teva Branded Pharmaceutical Products R&D, Inc.
2004-06-30 – 2004-09-30 · Exercise-induced Bronchospasm
What this study did
NCT00382889 · Chiesi Farmaceutici S.p.A.
2002-08 – 2004-09 · Asthma
What this study did
Other / comorbidity
NCT05527704 · Medical University of Warsaw
2021-12-31 – 2026-09-30 · TTN, Respiratory Failure, PPHN
What this study did
NCT05653024 · Philippe Bégin
2023-07-01 – 2025-05-05 · IgE-mediated Abdominal Pain
What this study did
NCT03745261 · Henan University of Traditional Chinese Medicine
2018-06-20 – 2020-06 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03449056 · Poitiers University Hospital
2019-01-11 – 2020-04 · Chronic Obstructive Pulmonary Disease, High-flow Nasal Cannula
What this study did
NCT02782052 · Assistance Publique - Hôpitaux de Paris
2016-07 – 2019-02 · Pulmonary Arterial Hypertension
What this study did
NCT03208894 · Armed Forces Hospital, Pakistan
2016-11-01 – 2017-06-30 · Transient Tachypnea of the Newborn
What this study did
NCT02731846 · GlaxoSmithKline
2016-06 – 2016-11 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02160548 · Sylhet M.A.G.Osmani Medical College
2015-04 – 2015-12 · Organophosphate Poisoning
What this study did
NCT01836016 · Henan University of Traditional Chinese Medicine
2013-05 – 2015-05 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01613326 · Novartis Pharmaceuticals
2012-06 – 2013-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01120691 · Novartis Pharmaceuticals
2010-04 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00669617 · Novartis
2008-04 – 2008-08 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 2/3 (3)
Asthma
NCT06657066 · King Edward Medical University
2021-12-06 – 2023-08-08 · Asthma Patients
What this study did
Other / comorbidity
NCT06815679 · Università degli Studi di Ferrara
2025-03-01 – 2026-07 · Acute Respiratory Failure, Pneumonia
What this study did
NCT00633919 · ALK-Abelló A/S
2006-07 – 2009-02 · Allergy
What this study did
Phase 2 (18)
Asthma
NCT06482294 · Università degli Studi di Ferrara
2024-06-18 – 2025-07-01 · Asthma
What this study did
NCT01252758 · Acerus Pharmaceuticals Corporation
2012-11 – 2015-10 · Asthma
What this study did
NCT01470755 · Assistance Publique - Hôpitaux de Paris
2012-01 – 2014-01 · Asthma
What this study did
NCT01899144 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-07 – 2013-10 · Asthma
What this study did
NCT01641692 · GlaxoSmithKline
2012-05 – 2013-02 · Asthma
What this study did
NCT01058863 · Teva Branded Pharmaceutical Products R&D, Inc.
2010-02 – 2010-06 · Asthma
What this study did
NCT00358488 · GlaxoSmithKline
2006-04 – 2007-01 · Pulmonary Disease, Chronic Obstructive
What this study did
Other / comorbidity
NCT05860244 · Assistance Publique - Hôpitaux de Paris
2024-09 – 2025-07 · Walking Capacity, Amyotrophic Lateral Sclerosis
What this study did
NCT04565847 · McMaster University
2020-11-30 – 2021-12-16 · Cough
What this study did
NCT02299375 · GlaxoSmithKline
2014-12-09 – 2016-06-30 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01958814 · University Hospital, Tours
2012-02 – 2015-07 · Chronic Respiratory Failure
What this study did
NCT01957293 · Prof. Dominique de Quervain, MD
2013-10 – 2014-02 · Memory Functions
What this study did
NCT00677729 · Queen's University
2008-11 – 2009-05 · Viral Bronchiolitis
What this study did
NCT00696540 · University Diego Portales
2008-06 – 2008-10 · Bronchiolitis, Respiratory Distress
What this study did
NCT00117182 · Syntara
2005-07 – 2006-08 · Lung Diseases, Obstructive
What this study did
Phase 1 (25)
Asthma
NCT06319183 · Tongji University
2024-03 – 2025-03 · Effect of Asthma Medication Salbutamol on Obesity
What this study did
NCT05791565 · GlaxoSmithKline
2023-04-03 – 2023-05-21 · Asthma
What this study did
NCT05366764 · Sanofi
2022-06-08 – 2023-02-24 · Asthma
What this study did
NCT04929626 · Ziauddin University
2022-01-01 – 2022-11-12 · Status Asthmaticus
What this study did
NCT01844401 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-04 – 2013-10 · Asthma
What this study did
NCT01056159 · Teva Branded Pharmaceutical Products R&D, Inc.
2010-01 – 2010-06 · Asthma
What this study did
NCT00673621 · Mannkind Corporation
2008-05 – 2008-12 · Asthma, Diabetes Mellitus
What this study did
Other / comorbidity
NCT07591558 · King Abdullah University Hospital
2026-06 – 2026-12 · Atelectases, Postoperative Pulmonary, Diabete Mellitus
What this study did
NCT06027606 · University of Alberta
2023-09-01 – 2025-09-25 · Healthy
What this study did
NCT06921291 · Khyber Teaching Hospital
2024-08-01 – 2024-12-31 · TTN
What this study did
NCT06139029 · Mardan Medical Complex
2022-11-15 – 2023-03-15 · Acute Bronchiolitis
What this study did
NCT04979923 · Sheikh Zayed Medical College
2021-07-01 – 2021-08 · COVID-19 Acute Respiratory Distress Syndrome
What this study did
NCT04488705 · Enterprise Therapeutics Ltd
2020-08-13 – 2021-05-19 · Healthy
What this study did
NCT03514615 · University Hospitals, Leicester
2018-01-10 – 2019-07-01 · Scarring
What this study did
NCT03436225 · Assiut University
2019-02 – 2019-03 · Bronchiolitis; Respiratory Syncytial Virus
What this study did
NCT05006235 · Ahmed Noaman
2014-02-01 – 2015-12-31 · Transient Tachypnea of the Newborn
What this study did
NCT01457261 · Royal Brompton & Harefield NHS Foundation Trust
2012-04 – 2014-11 · Idiopathic Pulmonary Fibrosis
What this study did
NCT02207452 · GlaxoSmithKline
2010-08-05 – 2011-07-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00549120 · GlaxoSmithKline
2007-08-15 – 2007-10-26 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 4 (52)
Asthma
NCT07426458 · University of Miami
2026-04-27 – 2028-04 · Asthma
What this study did
NCT06816342 · Beni-Suef University
2024-11-01 – 2025-02-10 · Asthmatic Patients, MDI, Aerosol Generating Procedure
What this study did
NCT05087693 · University of British Columbia
2021-11-01 – 2023-08-31 · Asthma and/or Exercise Induced Bronchoconstriction, Ozone Air Pollution
What this study did
NCT05084222 · Orion Corporation, Orion Pharma
2021-11-11 – 2023-06-30 · Asthma
What this study did
NCT03924635 · AstraZeneca
2019-08-01 – 2022-12-16 · Airway Inflammation, Asthma
What this study did
NCT03586544 · University of Nevada, Las Vegas
2018-09-18 – 2021-03-30 · Asthma in Children, Obesity, Childhood, Exercise Induced Bronchospasm
What this study did
NCT04750603 · Rambam Health Care Campus
2018-12-01 – 2020-04-15 · Asthma in Children
What this study did
NCT03363191 · GlaxoSmithKline
2018-03-07 – 2019-05-29 · Asthma
What this study did
NCT03493503 · Erasmus Medical Center
2017-04-05 – 2019-05-21 · Childhood Asthma With Status Asthmaticus
What this study did
NCT01721291 · Imperial College London
2012-10-01 – 2017-11-27 · CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, HEALTHY SUBJECTS
What this study did
NCT02654145 · GlaxoSmithKline
2016-03-17 – 2017-05-31 · Asthma
What this study did
NCT01471340 · Organon and Co
2012-01-09 – 2016-11-30 · Asthma
What this study did
NCT03044938 · Universidade Ibirapuera
2016-08-06 – 2016-11-21 · Asthma, Heart Rate Fast
What this study did
NCT02233803 · GlaxoSmithKline
2014-11-14 – 2015-12-11 · Asthma
What this study did
NCT02877537 · Central Hospital, Nancy, France
2008-10 – 2012-04 · Asthma
What this study did
NCT01338311 · University of Saskatchewan
2011-03 – 2012-03 · Asthma
What this study did
NCT00440245 · University of Saskatchewan
2007-02 – 2010-07 · Asthma, COPD
What this study did
NCT00900874 · All India Institute of Medical Sciences
2009-01 – 2010-05 · Bronchial Asthma
What this study did
NCT00530062 · Teva Branded Pharmaceutical Products R&D, Inc.
2007-07-25 – 2008-10-24 · Asthma
What this study did
NCT00487773 · Medical University of Lodz
2007-09 – 2008-09 · Asthma
What this study did
NCT00363480 · GlaxoSmithKline
2006-05-17 – 2007-09-14 · Asthma
What this study did
NCT00315744 · GlaxoSmithKline
2004-11-04 – 2007-04-12 · Asthma
What this study did
NCT00272753 · AstraZeneca
2004-04 – 2005-11 · Asthma
What this study did
NCT00273962 · Boehringer Ingelheim
2002-05 – 2003-11 · Asthma
What this study did
NCT02182713 · Boehringer Ingelheim
1998-05 – 1998-09 · Asthma
What this study did
Other / comorbidity
NCT04012138 · Nantes University Hospital
2019-12-20 – 2025-12-20 · Hyperkalemia
What this study did
NCT06158893 · Assiut University
2024-08 – 2025-10 · Preoperative Inhalation of Budesonide and Salbutamol in Children Undergoing Tonsillectomy
What this study did
NCT06036823 · Oman Medical Speciality Board
2023-10-01 – 2025-09-30 · Hyperkalemia, Potassium Imbalance, Electrolyte Imbalance, Electrolyte Disturbance
What this study did
NCT04606394 · Pulmonary Research Institute of Southeast Michigan
2020-12-02 – 2021-12-15 · COPD
What this study did
NCT03880903 · Assiut University
2020-07-20 – 2021-09-20 · Acute Bronchiolitis
What this study did
NCT02914652 · University of Aarhus
2016-10-15 – 2018-01-01 · Ventricular Septal Defect
What this study did
NCT03333395 · Ain Shams University
2017-02-01 – 2017-09-30 · Mechanically Ventilated Patients
What this study did
NCT02576626 · Wouter H. van Geffen
2015-12 – 2017-09-29 · COPD
What this study did
NCT02799784 · GlaxoSmithKline
2016-07-14 – 2017-04-27 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02371629 · Novartis Pharmaceuticals
2015-06-24 – 2016-11-16 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01903785 · University of British Columbia
2013-05 – 2016-08 · Bronchoconstriction, Inhaled Salbutamol, Cycling Performance
What this study did
NCT01978418 · Sture Andersson
2013-11 – 2015-12 · Postnatal Pulmonary Adaptation, Cesarean Section
What this study did
NCT02103374 · University Hospital, Tours
2012-01 – 2015-12 · Severe Chronic Obstructive Pulmonary Disease
What this study did
NCT02257372 · GlaxoSmithKline
2014-09-30 – 2015-03-24 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT05749523 · Vibeke Backer
2013-11 – 2014-09 · Healthy
What this study did
NCT01922271 · Novartis Pharmaceuticals
2013-08 – 2014-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT01691482 · GlaxoSmithKline
2012-07-23 – 2012-10-22 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT00783250 · IRCCS Azienda Ospedaliero-Universitaria di Bologna
2008-09 – 2012-07 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00911651 · University Hospital, Antwerp
2008-06 – 2008-08 · COPD
What this study did
Early phase / not applicable (50)
Asthma
NCT07037511 · University of British Columbia
2025-10-30 – 2030-12-31 · Asthma, Healthy, Effect of Drug
What this study did
NCT05550402 · Hat Yai Medical Education Center
2024-02-17 – 2024-06-30 · Asthma, Airway Obstruction, Airway Remodeling, Parasympathetic Nervous System Diseases
What this study did
NCT03556683 · University of North Carolina, Chapel Hill
2018-10-01 – 2024-06-06 · Moderate to Severe Asthma
What this study did
NCT04402658 · Norwegian School of Sport Sciences
2022-08-01 – 2023-12-20 · Sports Drug Abuse
What this study did
NCT04542005 · The University of Texas Health Science Center, Houston
2020-12 – 2023-07 · Asthma in Children
What this study did
NCT04896645 · Children's Hospital Los Angeles
2021-06-01 – 2022-06-22 · Asthma in Children
What this study did
NCT02252302 · University of British Columbia
2015-05 – 2021-05 · Exercise-induced Bronchoconstriction, Air Pollution
What this study did
NCT03620422 · McMaster University
2019-01-11 – 2020-01-31 · Asthma, Cough
What this study did
NCT03430505 · University of Nove de Julho
2017-06-10 – 2018-12-20 · Asthma
What this study did
NCT03296579 · University of British Columbia
2018-06 – 2018-12 · Asthma Acute, Asthma in Children
What this study did
NCT03042065 · Centre d'Investigation Clinique et Technologique 805
2017-03 – 2017-09 · Asthma
What this study did
NCT00876135 · Laval University
2008-12 – 2013-05 · Asthma
What this study did
NCT01073527 · Wolfson Medical Center
2009-01 – 2011-07 · Asthma
What this study did
NCT00162396 · Hadassah Medical Organization
started 1999-08 · Asthma
What this study did
Other / comorbidity
NCT07877519 · China National Center for Cardiovascular Diseases
2026-06-01 – 2028-06 · Paroxysmal Atrial Fibrillation
What this study did
NCT07350421 · Latakia University
2026-01-01 – 2028-03-01 · TTN
What this study did
CF Bronchodilationactive not recruiting
NCT03522831 · University of British Columbia
2018-05-01 – 2027-12-31 · Lung Diseases, Cystic Fibrosis
What this study did
NCT06426082 · Universidad de Almeria
2024-11-01 – 2026-08 · Cardiometabolic Diseases
What this study did
NCT06276231 · Oman Medical Speciality Board
2024-07-01 – 2026-05-01 · Renal Colic
What this study did
NCT07378605 · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
2026-01-01 – 2026-03-15 · Bariatric Surgery
What this study did
NCT05914285 · Yonsei University
2023-04-25 – 2025-07-21 · One-lung Ventilation, Chronic Obstructive Pulmonary Disease
What this study did
NCT03842839 · Guangzhou Institute of Respiratory Disease
2019-08-01 – 2025-05-07 · Airway Remodeling, Chronic Obstructive Pulmonary Disease
What this study did
NCT05099107 · Vastra Gotaland Region
2021-10-25 – 2025-03-17 · Congenital Myopathy, Neuromuscular Diseases, Musculoskeletal Diseases, Nemaline Myopathy, Centronuclear Myopathy, Myosin Storage Myopathy
What this study did
NCT06665711 · University of Health Sciences Lahore
2024-12-03 – 2025-03-10 · BRONCHIOLITIS
What this study did
NCT05932316 · Rambam Health Care Campus
2023-05-20 – 2024-12 · Bronchiectasis, Cystic Fibrosis, Primary Ciliary Dyskinesia, Primary Immune Deficiency, Bronchiolitis Obliterans
What this study did
NCT05786950 · The First Affiliated Hospital of Guangzhou Medical University
2023-01-01 – 2024-09-01 · Chronic Obstructive Pulmonary Disease
What this study did
NCT05589441 · First Affiliated Hospital Xi'an Jiaotong University
2022-10-28 – 2024-01-10 · Liver Transplantation
What this study did
NCT04615611 · University of Copenhagen
2020-11-07 – 2021-11-07 · Healthy
What this study did
NCT04558190 · University of Copenhagen
2020-09-02 – 2021-11-01 · Insulin Resistance
What this study did
NCT03902106 · University of Copenhagen
2019-03-28 – 2021-06-30 · Healthy
What this study did
NCT02523833 · University of Sao Paulo General Hospital
2015-09-01 – 2017-11-20 · Hypersensitivity Pneumonitis, Airway Disease Small
What this study did
NCT02925130 · University Hospital, Grenoble
2016-10 – 2017-09-28 · Adrenergic Beta-2 Agonist Effect, Albuterol Effect
What this study did
NCT02686086 · Beaumont Hospital
2016-02 – 2017-07 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02159196 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-07 – 2017-06 · Respiratory Failure
What this study did
NCT02863835 · Guy's and St Thomas' NHS Foundation Trust
2016-04 – 2017-06 · Transplantation, Heart-Lung, Chronic Lung Allograft Dysfunction, Bronchiolitis Obliterans Syndrome
What this study did
NCT02818270 · Chang Gung University
2016-06 – 2016-12-31 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02255630 · University of British Columbia
2015-01 – 2016-08 · Ergogenic Athletic Performance
What this study did
NCT02551276 · University of Copenhagen
2013-11 – 2015-11 · Muscle Hypertrophy in Healthy Young Men
What this study did
NCT02296047 · Zhujiang Hospital
2014-12 – 2015-05 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT01714401 · Medical University of Gdansk
2012-03 – 2013-12-31 · Influence of Nebulized Bronchodilatators on Selected, Electrophysiological Parameters
What this study did
NCT01415596 · Bispebjerg Hospital
2011-08 – 2013-08 · Ergogenic Effects of Salbutamol in Healthy Males
What this study did
NCT00608790 · University of Cape Town
2008-02 – 2013-04 · Tuberculosis
What this study did
NCT01521572 · Rio de Janeiro State University
2011-06 – 2012-09 · Smoking, Airway Obstruction
What this study did
NCT01447069 · Rabin Medical Center
2011-10 – 2012-03 · Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure
What this study did
NCT00981851 · Radboud University Medical Center
2009-09 – 2011-05 · Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Smoking, Bronchodilation
What this study did
NCT01067534 · University of Patras
2010-02 – 2011-01 · Bronchodilation
What this study did
NCT00180843 · Imperial College London
2005-09 – 2008-02 · Chronic Obstructive Pulmonary Disease
What this study did
NCT00498251 · University Hospital, Geneva
2004-09 – 2007-06 · Lung Injury, Acute, Thoracotomy, Anesthesia, Intensive Care, Surgical, Extravascular Lung Water
What this study did
NCT00114478 · Kern Medical Center
2003-11 – 2006-05 · Bronchiolitis
What this study did
Used as active comparator (28)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (7)
Asthma
NCT00861926 · Chiesi Farmaceutici S.p.A.
2009-03-20 – 2010-12-07 · Asthma
What this study did
NCT00064389 · Sumitomo Pharma America, Inc.
2003-01 – 2005-07 · Asthma
What this study did
NCT00646620 · AstraZeneca
2003-04 – 2003-09 · Asthma
What this study did
NCT00685425 · Sumitomo Pharma America, Inc.
2002-10 – 2003-03 · Asthma, Bronchoconstriction
What this study did
NCT00667407 · Sumitomo Pharma America, Inc.
2000-11 – 2002-08 · Asthma
What this study did
Other / comorbidity
Phase 2 (10)
Asthma
NCT03643874 · Concentrx Pharmaceuticals, Inc.
2018-06-30 – 2018-09-30 · Asthma
What this study did
NCT02427165 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2015-04 – 2015-11 · Asthma
What this study did
NCT02162784 · Intech Biopharm Ltd.
2013-02 – 2014-08 · Asthma
What this study did
NCT01425801 · AstraZeneca
2011-08-01 – 2012-02-01 · Asthma
What this study did
NCT00685022 · Sumitomo Pharma America, Inc.
2003-06 – 2003-08 · Asthma
What this study did
NCT00684866 · Sumitomo Pharma America, Inc.
2003-01 – 2003-07 · Asthma
What this study did
NCT00685347 · Sumitomo Pharma America, Inc.
2003-01 – 2003-06 · Asthma, Bronchoconstriction
What this study did
NCT00684827 · Sumitomo Pharma America, Inc.
2002-10 – 2003-02 · Asthma
What this study did
NCT01656811 · Sumitomo Pharma America, Inc.
2001-10 – 2002-07 · Asthma
What this study did
Other / comorbidity
NCT02542254 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2015-10 – 2015-12 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 1 (2)
Asthma
NCT03373409 · Concentrx Pharmaceuticals, Inc.
2017-11-30 – 2018-07-25 · Asthma
What this study did
Other / comorbidity
NCT03059017 · British University In Egypt
2017-02-05 – 2017-02-05 · Drug Effect, Pulmonary Disease
What this study did
Phase 4 (6)
Asthma
NCT05667727 · Oman Medical Speciality Board
2023-10-15 – 2025-06-01 · Shortness of Breath, Asthma in Children, Epinephrine Causing Adverse Effects in Therapeutic Use, Salbutamol Adverse Reaction
What this study did
NCT06918418 · Children's Hospital and Institute of Child Health, Multan
2024-01-01 – 2024-07-15 · Asthma Exacerbation, Children
What this study did
NCT00831376 · University of Dundee
2009-01 – 2012-04 · Asthma
What this study did
NCT00830882 · University of Dundee
2009-01 – 2010-01 · Asthma
What this study did
NCT00667797 · Sumitomo Pharma America, Inc.
2003-03 – 2005-05 · Asthma, COPD
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT03814954 · Makassed General Hospital
2019-01-01 – 2021-08-31 · Respiratory Distress Score
What this study did
NCT02812979 · University Hospital, Tours
2016-06 – 2018-04-27 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02069665 · Liaoning University of Traditional Chinese Medicine
2011-12 – 2013-08 · Pneumonia
What this study did
Studied as part of a combination product (2)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Asthma
NCT02182700 · Boehringer Ingelheim
1998-07 – 1999-12 · Asthma
What this study did
Early phase / not applicable (1)
Asthma
NCT03271905 · Universidade Federal do Rio Grande do Norte
2017-04-10 – 2019-12-10 · COPD, Asthma
What this study did
Appears in other studies (36)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (18)
Asthma
NCT03562195 · GlaxoSmithKline
2018-08-29 – 2022-09-07 · Asthma
What this study did
NCT03468790 · Shanghai Biomabs Pharmaceutical Co., Ltd.
2018-05-09 – 2021-03-09 · Asthma, Allergic
What this study did
NCT03816267 · Suez Canal University
2018-05-15 – 2019-03-31 · Bronchial Asthma
What this study did
NCT02478398 · Merck Sharp & Dohme LLC
2015-07-20 – 2018-11-19 · Rhinitis, Allergic, Seasonal
What this study did
NCT02414854 · Sanofi
2015-04-27 – 2017-11-23 · Asthma
What this study did
NCT02528214 · Sanofi
2015-10-15 – 2017-11-13 · Asthma
What this study did
NCT02127697 · Novartis Pharmaceuticals
2015-03 – 2017-05 · Asthma
What this study did
NCT02483975 · GlaxoSmithKline
2015-10-09 – 2016-06-21 · Asthma
What this study did
NCT02513160 · Teva Branded Pharmaceutical Products R&D, Inc.
2015-09-30 – 2016-03-31 · Persistent Asthma
What this study did
NCT02141854 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-06 – 2015-09 · Asthma
What this study did
NCT02139644 · Teva Branded Pharmaceutical Products R&D, Inc.
2014-06 – 2015-09 · Asthma
What this study did
NCT02040779 · Teva Branded Pharmaceutical Products R&D, Inc.
2013-12-26 – 2014-12-24 · Persistent Asthma
What this study did
Other / comorbidity
NCT02257385 · GlaxoSmithKline
2014-10-15 – 2015-05-04 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT01490125 · Novartis Pharmaceuticals
2011-10 – 2012-08 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03914638 · University of Aarhus
2019-04-01 – 2021-10-31 · Myasthenia Gravis
What this study did
Phase 2 (6)
Asthma
NCT03707678 · GlaxoSmithKline
2019-01-21 – 2019-12-23 · Asthma
What this study did
NCT03012061 · GlaxoSmithKline
2017-01-25 – 2018-05-30 · Asthma
What this study did
NCT01854047 · Sanofi
2013-06 – 2015-04 · Asthma
What this study did
Other / comorbidity
NCT05987371 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-08-23 – 2024-04-23 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03345407 · GlaxoSmithKline
2017-11-28 – 2019-01-10 · Pulmonary Disease, Chronic Obstructive
What this study did
Phase 4 (10)
Asthma
NCT07436104 · MAHAN Trust
2004-01-01 – 2023-08-31 · Hypertension (HTN), Diarrhea, Pneumonia, Malaria Fever, COPD, Asthma (Diagnosis), Diarrhea Chronic
What this study did
NCT03199976 · Helsinki University Central Hospital
2016-04-20 – 2020-11-18 · Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
What this study did
NCT00189436 · Deborah Gentile
2003-03 – 2009-01 · Asthma
What this study did
NCT00070707 · Organon and Co
2003-04-03 – 2003-11-26 · Rhinitis, Allergic, Seasonal, Asthma
What this study did
Other / comorbidity
NCT07809555 · Yi-Han Hsiao
2021-08-12 – 2024-11-29 · Small Airway Dysfunction
What this study did
NCT02405598 · National Taiwan University Hospital
2013-10 – 2016-06 · Pompe Disease
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT01655199 · Laval University
2012-09 – 2014-07 · Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease, Dyspnea
What this study did

Competitive landscape

This mechanism is crowded: 17 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Albuterol (Ventolin): this drugApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair)
ApprovedUS marketing discontinued (overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere)
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Olodaterol
Approved(overall)
Small moleculeBeta-2 adrenergic receptor
Reliable signal(overall)
NCT01013753: Primary FEV1 AUC 0-24h response: placebo -0.004 L; olodaterol 2 mcg 0.135 L, 5 mcg 0.178 L, 10 mcg 0.201 L, and 20 mcg 0.225 L; each olodaterol dose vs placebo p<0.0001.
NCT00467740: Trough FEV1 Response After 4 Weeks (Baseline and 4 weeks): Olo 2 mcg qd 0.083 Liter (Standard Error 0.032) | Olo 5 mcg qd 0.09 Liter (Standard Error 0.032) | Olo 10 mcg qd 0.08 Liter (Standard Error 0.032) | Olo 20 mcg qd 0.15 Liter (Standard Error 0.032) vs Placebo 0.004 Liter (Standard Error 0.034)
Olodaterol / Tiotropium Bromide
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Umeclidinium / Vilanterol
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race
TozorakimabPhase 2Monoclonal antibodyIL-33Partial signal
NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed
Umeclidinium (Incruse Ellipta)Phase 2Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873)
NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05)
VerekitugPhase 2Monoclonal antibodyTSLP receptorReliable signal
NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02)
AMG 691Phase 1——not yet gradedNo reviewed efficacy summary in this indication
AZD0449Phase 1—JAK1Partial signalFeatured results are safety only in this race
BAT2606Phase 1Monoclonal antibodyIL-5Partial signal
NCT05576454: In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%.
BriquilimabPhase 1Monoclonal antibodyKITPartial signalFeatured results are safety only in this race
CDX-622Phase 1Multispecific antibodyTSLP + SCF/KITnot yet gradedNo reviewed efficacy summary in this indication
PF-08103402Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Amphastar A006Discontinued—Beta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication

Large race: only the 77 furthest-along competitors are listed; 15 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow albuterol (Ventolin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Early phase / not applicableTTNNot yet recruiting
Est. primary completion 2027-01-01 · NCT07350421 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1AsthmaRecruiting
Est. primary completion 2027-04-16 · NCT06433921 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableLung Diseases, Cystic FibrosisActive not recruiting
Est. primary completion 2027-12-31 · NCT03522831 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 4AsthmaRecruiting
Est. primary completion 2028-04 · NCT07426458 · CT.gov ↗
What to watch
June 2028 (1)
Early phase / not applicableParoxysmal Atrial FibrillationRecruiting
Est. primary completion 2028-06 · NCT07877519 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Early phase / not applicableAsthmaRecruiting
Est. primary completion 2029-12-31 · NCT07037511 · CT.gov ↗
What to watch

See the full readout calendar ↗